SCHEDULE: NEA Reports Ownership Change in Trevi Therapeutics

New Enterprise Associates reports a change in beneficial ownership percentage in Trevi Therapeutics due to an increase in the issuer's total outstanding shares.

Summary

• New Enterprise Associates (NEA) and affiliated entities filed Amendment No. 9 to their Schedule 13D regarding Trevi Therapeutics, Inc.
• The reporting persons beneficially own 15,074,080 shares of common stock, including warrants.
• The filing reflects a decrease in the reporting persons' ownership percentage to 10.5% from previous levels.
• The change in percentage is attributed solely to an increase in the total number of outstanding shares of Trevi Therapeutics, rather than any sale or disposition of shares by the reporting persons.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting a change in ownership percentage due to share dilution rather than a change in investment sentiment.

Positives

• The filing confirms that the reporting persons have not sold or disposed of any shares in the last 60 days.
• The change in ownership percentage is purely technical, resulting from the issuer's capital structure changes rather than a divestment by the major shareholder.

Negatives

• The reporting persons' total ownership percentage has been diluted due to the increase in the issuer's outstanding share count.

Risks

• Potential future dilution of existing shareholders if the issuer continues to issue additional shares.
• Market volatility associated with significant shareholder activity or changes in the issuer's capital structure.

Future Outlook

The reporting persons state they may continue to evaluate the business and prospects of the issuer and may acquire or dispose of additional shares depending on market conditions.

Management Comments

• The reporting persons disclaim beneficial ownership of the Firm Shares other than those shares which such person owns of record.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory update for venture capital firms managing their reporting obligations following changes in a portfolio company's share count, common in the biotech sector during capital raises or warrant exercises.

Comparison to Industry Standards

• The filing adheres to standard SEC disclosure requirements for beneficial owners holding over 5% of a company's equity.
• The use of a joint filing agreement is consistent with institutional investor practices for managing multiple affiliated funds.

Legal Proceedings

• None reported.

Related Party Transactions

• None reported.

Stakeholder Impact

• Existing shareholders may note the dilution of the major shareholder's position, which is a standard outcome of equity issuance.

Next Steps

• Continued monitoring of the issuer's share count and potential future filings by the reporting persons.

Key Dates

Keywords

Trevi Therapeutics, New Enterprise Associates, Schedule 13D, Beneficial Ownership, Biotech, Equity Dilution